Trichomonas Vaginalis Recurrence Among HIV+ Women
Completed · Phase 4
Conditions studied: Trichomonas Infections, HIV Infections
In brief
The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.
Key facts
- Study ID
- NCT01018095
- Run by
- Tulane University Health Sciences Center
- People needed
- 270
- Starts
- 2005-05-01
- Expected to finish
- 2009-08-01
- Last updated by the study team
- 2016-12-20
Who can join
Age: 18 and older. Sex: female. Healthy volunteers: not accepted.
You may qualify if…
- Female
- 18 years or older
- HIV-positive
- TV positive by either wet preparation or culture
- ability to refrain from all alcohol use for 24 hours before and after taking oral metronidazole
- willing to take metronidazole treatment
You may not qualify if…
- pregnant
- incarcerated
- previously enrolled
- currently taking disulfiram
- alcoholism or known liver damage
- medical contraindications to metronidazole
- treated with metronidazole within the previous 14 days
- requires treatment for B.V. per Amsel's criteria
Where it is running
- HIV Outpatient Clinic — New Orleans, Louisiana, United States
- NOAIDS — New Orleans, Louisiana, United States
- Crossroads Clinic — Jackson, Mississippi, United States
- Thomas St Clinic — Houston, Texas, United States
- Northwest Clinic — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.